BDBM191623 US20240317756, Compound 19::US9181263, 19::US9278100, 19

SMILES CN(CCn1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc12)C(=O)C=C

InChI Key InChIKey=ZFHREWWRBHSDLZ-UHFFFAOYSA-N

Data  15 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 191623   

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 1.58nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2016
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 535nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2016
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 28.2nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2016
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 6.62nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2016
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 6.00E+3nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 μM ATP.). For enzyme in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2016
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 1.58nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 535nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 28.2nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 6.62nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 6.00E+3nMAssay Description:IC50s were determined using the in vitro HotSpot kinase assay (purified enzymes, 33P-ATP, an appropriate substrate and 1 uM ATP.). Reaction condition...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/3/2017
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 1.58nMAssay Description:For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ITK/TSK(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 535nMAssay Description:For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2025
Entry Details
Go to US Patent

TargetEpidermal growth factor receptor(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 28.2nMAssay Description:For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Lck(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 6.62nMAssay Description:For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2025
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pharmacyclics

US Patent
LigandPNGBDBM191623(US9181263, 19 | US9278100, 19 | US20240317756, Com...)
Affinity DataIC50: 6.00E+3nMAssay Description:For enzyme inhibition assays, compounds were tested in range of ten concentrations from 10 uM to 0.0005 uM using purified enzymes and the Hotspot kin...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2025
Entry Details
Go to US Patent